This 3-day forum is the “must attend” event for those senior decision-makers looking to drive their medical affairs teams and departments and enhance their KOL & stakeholder engagement at all levels.

Along with our exclusivenetworking dinner for all participants, the event will feature excellent networking opportunities and the chance to strengthen your contacts within the Medical Affairs community. The 2018 event was a sell-out so please make sure you book early to avoid disappointment.

Why Attend in 2019?

This event will enable you to:

  1. Understand how medical affairs are at the forefront of new pharmaceutical industry commercial models and what needs to be done to maximise success.
  2. Discover which are the most intelligent ways to map and engage with KOLs and other prescribers, payers, patient groups, pharmacies and tomorrow’s stakeholders.
  3. Measure the performance of your medical affairs team and individuals.
  4. Benchmark with experts to find out the best practices in late phase research, especially observational studies, patient registries and investigator-initiated studies.
  5. Discover how medical scientific liaisons, in support of commercial teams, are crucial to the communication of effectiveness, safety and cost effectiveness.
  6. Learn how the medical affairs role can engage KOLs & enhance value for medical devices due to their unique product lifecycle and characteristics.
  7. Get real-life experiences of medical affairs capabilities development in smaller Pharma, Biotech & MedTech companies.
Request agenda here for complete speaker list

Industry experts: Large & Medium Pharma

Vice President and Head of External Engagement & Policy Neurology Patient Value Unit

Medical Excellence Director, Region Europe
Novartis Oncology

Vice President, Global Medical Affairs Head, Respiratory

Head of Global Medical Information 
Ipsen Pharma, UK

VP, Medical Affairs, Norgine
Excellence Lead, Pinnacle Wellbeing Services, UK

Senior Director, Enterprise Benefit Risk Medical Director
Worldwide Medical and Safety | Global Medical Impact Assessment
Pfizer, USA

Senior Director, Global Medical Science Liaison
Philips, USA

EMEA Neurology & Immunology Medical Affairs Director
Merck Group, Poland

Senior Medical Director, US Medical Affairs Lead – Neuroscience
Otsuka Pharmaceutical Development and Commercialization, USA

Medical Director, Region Europe, MSL and Digital Transformation

Director, Biostatistics
Celgene, USA

MSL Manager
Janssen, Pharmaceutical Companies of Johnson and Johnson, UK

Digital Health Innovation Manager
Bayer Business Services                       

McKinsey & Co., Switzerland

Industry experts: Smaller Pharma, Biotech & MedTech

Head Medical Affairs Global Medical and Scientific Affairs CPS
Roche Diagnostics International, Switzerland

SVP Head Clinical Development
BTG International

Vice President Medical Affairs
Pharming Group, Netherlands

Medical Director CEEMERIT
Kyowa Kirin Pharma, Czech Republic

Vice President Medical Affairs
Gelesis, USA

Chief Medical Officer, Surgical Products & Exogenous
Bioventus, USA


External Stakeholders

European Medical Association, Belgium

Associate Director of Medicines Optimisation, DGS & Swale CCGs

Patient View, UK

Managing Director, Center for Research and Interdisciplinarity (CRI), France
Board member Healthcare Data Institute

Digital Health Innovation Manager
Bayer Business Services

Experienced Solution Provider

CEO, Head of Clinical Services, Senior Executive Coach
Pinnacle Wellbeing 247

Senior Vice President, Business Partnerships

Vynamic, UK

PharmaReview, UK

Principal Consultant Patient Centred Outcomes
Open Health, UK

Account Director
OPEN Health Medical Communications, UK

Director, Consulting
Syneos Health

Principal, Real-World & Late Phase
Syneos Health

Request agenda here for complete speaker list

Pictures from recent MedAffairs Leaders Forum. Imagine being there...

The first day will feature several keynote presentations from VP-Level thought leaders on shaping and leading the medical affairs departments, justifying medical affairs performance through innovative metrics and tracking effectiveness of the function as an essential element of today’s pharmaceutical companies. They will be discussing the strategic drivers for medical affairs, and guidance on how to make best use of this vital function.